Human serum and glucocorticoid-inducible kinase-like kinase (SGKL) phosphorylates glycogen syntheses kinase 3 beta (GSK-3beta) at serine-9 through direct interaction.

Fangyan Dai,Long Yu,Hua He,Yongjing Chen,Jianqiang Yu,Yumei Yang,YueFang Xu,Wenhai Ling,Shouyuan Zhao
DOI: https://doi.org/10.1016/S0006-291X(02)00349-2
IF: 3.1
2002-01-01
Biochemical and Biophysical Research Communications
Abstract:Serum and glucocorticoid-inducible kinase-like kinase (SGKL) has been identified as a new integrator that decodes lipid signals produced by the activation of phosphoinositide 3-kinase (PI3K). SGKL is activated via its lipid-binding domain (phox homology domain) in response to PI3K signaling. However, downstream targets of SGKL as well as the role of SGKL as a mediator in PI3K signaling in human tissues remain to be established. In this study, we identified human glycogen synthase kinase 3 beta (GSK-3β) as a specific interacting partner with SGKL in a yeast two-hybrid screening of human brain cDNA library. The association between these two proteins is confirmed independently in human embryonic kidney (HEK293) cells by co-immunoprecipitation. Furthermore, the kinase activity of wild-type SGKL was required for the in vitro phosphorylation of a GSK-3 crosstide fusion protein at serine-21/9 as demonstrated with a Phospho-GSK-3α/β (Ser21/9) specific antibody. The present results provide strong evidences that SGKL could utilize GSK-3β as a direct downstream target by phosphorylating GSK-3β at serine-9.
What problem does this paper attempt to address?